Observational studyScientific reports2023
Diagnosis and treatment patterns among patients with newly diagnosed Helicobacter pylori infection in the United States 2016-2019.
Observational study in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 30 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
30 citing papers in PubMed, 1 synthesis or guideline pooled it, 39 citations in OpenAlex.
- Quality indicators for upper GI endoscopy.Gastrointestinal endoscopy · 2025Guideline
- Comparative Efficacy of Potassium-Competitive Acid Blocker-Based Triple Therapy with Tegoprazan versus Vonoprazan forGut and liver · 2025Trial
- Prevalence of Helicobacter pylori Exposure and Risk Factors Among BRCA1 and BRCA2 Carriers.International journal of cancer · 2026Article
- Review Article: Implementation Challenges in Helicobacter pylori Management: Bridging Evidence and Real-World Practice.Alimentary pharmacology & therapeutics · 2026Review
- Gastric Epithelium from BRCA1 and BRCA2 Carriers Harbors Increased Double-Stranded DNA Damage and Enhanced Growth Potential.Molecular cancer research : MCR · 2026Article
- A Quality Improvement Initiative to Increase Helicobacter pylori Testing and Eradication Among Patients Diagnosed With Peptic Ulcer Disease in a U.S. Safety-Net Hospital.Journal of clinical gastroenterology · 2026Article
- High Levels ofMicroorganisms · 2026Article
- Practice Tips From the UpdatedGastroenterology & hepatology · 2026Article
- Whole genome sequence analysis ofiScience · 2025Article
- Gastric epithelium frombioRxiv : the preprint server for biology · 2025Article
- Why internists should care about Helicobacter pylori: recapitulating gastric cancer prevention.Internal and emergency medicine · 2025Article
- Current Understanding of Optimal Prevention of Helicobacter pylori-Induced Cancer.Gastroenterology clinics of North America · 2025Review
- Quality Indicators for Upper GI Endoscopy.The American journal of gastroenterology · 2025Article
- Co-occurrence patterns of esophageal and stomach cancer across 204 countries and territories: a spatial correspondence and systematic analysis.Frontiers in oncology · 2025Article
- Accelerating progress to reduce the cancer burden through prevention and control in the United States.Journal of the National Cancer Institute · 2025Article
- Article
- The use of real-world evidence to generate cost analysis of antibiotic susceptibility testing (AST) in patients withHeliyon · 2024Article
- Article
- Current and Future Perspectives on the Management ofAntibiotics (Basel, Switzerland) · 2024Review
- Impact of Helicobacter pylori Infection and Treatment on Colorectal Cancer in a Large, Nationwide Cohort.Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2024Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 1 institution in 1 country.
Funding
Abstract
Approximately 36% of the United States (US) population is infected with Helicobacter pylori (HP), a known major risk factor for peptic ulcer disease and gastric cancer. HP eradication reduces the rate of complications; however, the benefits are undermined by rising rates of HP eradication treatment failure. This real-world observational cohort analysis aims to describe HP diagnostic and treatment patterns among insured patients in the US. Using diagnoses, lab results, and treatment patterns, we identified adults (18+) with new diagnoses of HP in the Veradigm Health Insights EHR Database linked to Komodo claims data (1/1/2016-12/31/2019). Patients were required to have ≥ 12 months of data pre-/post-index. We captured patient characteristics, HP-related diagnostic testing, and the use of US guideline-recommended HP eradication regimens. HP eradication rates following first-line eradication treatment were measured among patients with available lab results. Overall, 31.8% of the 60,593 included patients did not receive guideline-recommended treatment. Among the 68.2% (41,340) with first-line treatment, 80.2% received clarithromycin-based triple therapy, and 6.6% received bismuth quadruple therapy. Of the 4569 patients with a repeated course of eradication therapy, 53.4% received the same regimen as their first-line, the majority (90.7%) of whom received two rounds of clarithromycin-based triple therapy. Among the 2455 patients with results of HP non-serology testing following first-line treatment, the 180-day eradication rate was 80.2% overall, with differences based on treatments and demographics. This study highlights gaps between guideline-recommended HP management and real-world patterns, underscoring the need to improve HP testing, treatment, and follow-up practices.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.